Antivenom fails the people who need it most: the human cost of envenoming

The problem

Envenoming is a treatable medical emergency that still kills and maims at the scale of a major cancer, almost entirely among people the global health system overlooks. The paradox: a specific, effective therapy (antivenom) has existed since the 1890s, yet the people who need it usually cannot get a safe, effective, affordable dose in time.

Who is harmed

• Deaths. Roughly 1.8–2.7 million envenomings a year cause an estimated 81,410–137,880 deaths.
• Disability. Three to four times as many survivors are left with amputations, disfigurement, chronic kidney damage, blindness, or contractures — on the order of 300,000–400,000 people a year, destroying the earning capacity of agricultural workers.
• The rural poor. Victims are concentrated in farming and herding communities in tropical Asia, sub-Saharan Africa, and Latin America. India alone accounts for roughly half of global snakebite deaths (~58,000/year); South Asia for ~70%.
• Children. Lower body mass means children receive a higher venom dose per kilogram and deteriorate faster; paediatric mortality is disproportionately high for both snakebite and scorpion stings.

Scope

Snakebite was re-designated a WHO priority Neglected Tropical Disease in 2017; in 2019 WHO set a target to halve deaths and disability by 2030. Progress is constrained not by a single missing invention but by interacting failures — scientific, economic, regulatory, and logistical. Scorpions and spiders are included because they share the same antivenom production logic, access geography, and pattern of neglect, while differing in toxinology and evidence base.

References

• WHO, Snakebite envenoming fact sheets and 2019 global strategy
• Roberts et al., "Global mortality of snakebite envenoming 1990–2019," Nat Commun (2022)
• Systematic review/meta-analysis of global snakebite morbidity and mortality, PLOS/PMC (2024)